Stay updated on Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial
Sign up to get notified when there's something new on the Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial page.

Latest updates to the Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial page
- Check5 days agoChange DetectedThe page has been updated to include new information about Medullary Thyroid Cancer and its associated study, while significant details regarding the study's purpose and eligibility criteria have been removed.SummaryDifference12%
- Check13 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to February 27, 2025.SummaryDifference0.2%
- Check20 days agoChange DetectedThe page has been updated to reflect a new version release, moving from v2.14.2 to v2.14.3, and the last update date has changed from February 27, 2025, to March 25, 2025.SummaryDifference0.2%
- Check27 days agoNo Change Detected
- Check49 days agoChange DetectedThe webpage has updated its date references to include new dates in February 2025, while older dates have been removed.SummaryDifference1.0%
- Check70 days agoChange DetectedThe webpage has updated its timelines for disease progression metrics, extending some durations from 35 months to 39 months, and has removed several outdated dates and metrics. Additionally, there is a notice regarding heavy traffic affecting service performance.SummaryDifference2%
- Check78 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.0%
Stay in the know with updates to Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial page.